Materials and Methods

General Considerations
Commercially available 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (Lyso C 16 PC-OH) and 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (Lyso C 18 PC-OH) were used as obtained from Avanti® Polar Lipids. N-Boc-L-His(Trt)-OH, 2,4,6-trichlorobenzoyl chloride (TCBC), triethylamine (Et 3 N), 4-dimethylaminopyridine (DMAP), trifluoroacetic acid (TFA), triethylsilane (TES), oleic acid, N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (EDC.HCl), sodium 2-mercaptoethanesulfonate (MESNA), 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid (HEPES) sodium salt and 8-hydroxypyrene-1,3,6-trisulfonic acid (HPTS) were obtained from Sigma-Aldrich. Texas Red ® 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt (Texas Red ® DHPE) was obtained from Life Technologies. Deuterated chloroform (CDCl 3 ), methanol (CD 3 OD) and dimethyl sulfoxide (d 6 -DMSO) were obtained from Cambridge Isotope Laboratories. All reagents obtained from commercial suppliers were used without further purification unless otherwise noted. Analytical thin-layer chromatography was performed on E. Merck silica gel 60 F 254 plates. Compounds, which were not UV active, were visualized by dipping the plates in a ninhydrin or potassium permanganate solution and heating. Silica gel flash chromatography was performed using E. Merck silica gel (type 60SDS, 230-400 mesh 1 H NMR) spectra were recorded on a Varian VX-500 MHz or Jeol Delta ECA-500 MHz spectrometers, and were referenced relative to residual proton resonances in CDCl 3 (at 7.24 ppm), CD 3 OD (at 4.87 or 3.31 ppm) or d 6 -DMSO (at 2.50 ppm). Chemical shifts were reported in parts per million (ppm, δ) relative to tetramethylsilane (δ 0.00).
1 H NMR splitting patterns are assigned as singlet (s), doublet (d), triplet (t), quartet (q) or pentuplet (p). All first-order splitting patterns were designated on the basis of the appearance of the multiplet. Splitting patterns that could not be readily interpreted are designated as multiplet (m) or broad (br). Carbon nuclear magnetic resonance ( 13 C NMR) spectra were recorded on a Varian VX-500 MHz or Jeol Delta ECA-500 MHz spectrometers, and were referenced relative to residual proton resonances in CDCl 3 
1-palmitoyl-2-(His)-sn-glycero-3-phosphocholine (1).
-sn-glycero-3-phosphocholine (6, 15.0 mg, 15.4 µmol) in 2 mL of TFA/CH 2 Cl 2 /TES (0.9:0.9:0.2) was stirred at r.t. for 45 min. After removal of the solvent, the residue was dried under high vacuum for 3 h. Then, the corresponding residue was diluted in MeOH (250 µL), filtered using a 0.2 µm syringe-driven filter, and the crude solution was purified by HPLC, affording 7.0 mg of the lysolipid 1 as a colorless film [62%, t R = 8.0 min (Zorbax SB-C18 semipreparative column, 50% Phase A in Phase B, 5 min, and then 5% Phase A in Phase B, 10 min)].
1 H NMR (CD 3 OD, 500.13 MHz, δ): 
1-oleoyl-2-[N-Boc-L-His(Trt)]-sn-glycero-3-phosphocholine (7).
A solution of 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (Lyso C 18 PC-OH, 50.0 mg, 95.8 µmol), N-Boc-L-His(Trt)-OH (119.2 mg, 239.5 µmol), DMAP (70.2 mg, 574.8 µmol) and Et 3 N (46.7 µL, 335.3 µmol) in CDCl 3 (7.5 mL) was stirred at r.t. for 10 min. Then, TCBC (97.3 µL, 622.7 µmol) was added. After 12 h stirring at r.t., H 2 O (250 uL) was added to quench the acid chloride, and the solvent was removed under reduced pressure to give a pale yellow solid. The corresponding residue was dissolved in MeOH (1 mL), filtered using a 0.2 µm syringe-driven filter, and the crude solution was purified by HPLC, affording 72.3 mg of 7 as a white foam [75%, t R = 11.4 min (Zorbax 1-oleoyl-2-(His)-sn-glycero-3-phosphocholine (4) . A solution of 1-oleoyl-2-[N-Boc-L-His(Trt)]-sn-glycero-3-phosphocholine (7, 15.0 mg, 15.0 µmol) in 2 mL of TFA/CH 2 Cl 2 /TES (0.9:0.9:0.2) was stirred at r.t. for 45 min. After removal of the solvent, the residue was dried under high vacuum for 3 h. Then, the corresponding residue was diluted in MeOH (250 µL), filtered using a 0.2 µm syringe-driven filter, and the crude solution was purified by HPLC, affording 8. 
Synthesis of Thioesters
MESNA oleoyl thioester (2).
1 A solution of oleic acid (189.2 mg, 670.0 µmol) in CH 2 Cl 2 (5 mL) was stirred at 0 ºC for 10 min, and then DMAP (7.4 mg, 60.9 µmol) and EDC.HCl (128.4 mg, 670.0 µmol) were successively added. After 10 min stirring at 0 ºC, sodium 2-mercaptoethanesulfonate 2 (MESNA, 100.0 mg, 609.1 µmol) was added. After 5 h stirring at r.t., the mixture was extracted with H 2 O (2 × 3 mL) and the combined aqueous phases were washed with EtOAc (3 mL). 
1-oleoyl-2-[His-(oleoyl)]-sn-glycero-3-phosphocholine (5).
1-oleoyl-2-(His)-snglycero-3-phosphocholine (4, 2.00 mg, 3.04 µmol) and MESNA oleoyl thioester (2, 1.30 mg, 3.04 µmol) were dissolved in 608 µL of 100 mM HEPES buffer pH 7.5 and stirred under N 2 at r.t. After 24 h, the corresponding mixture was filtered using a 0.2 µm syringe-driven filter, and the crude solution was purified by HPLC, affording 1.43 mg of the phospholipid 5 as a colorless oil [51%, t R = 8.7 min (Zorbax SB-C18 semipreparative column, 100 % Phase B, 15. Micelle Sizes: Critical Micelle Concentrations (cmc's) 100.0 µL of aqueous solutions (100 µM, 10 µM and 1 µM) of the precursors (1, 2 and 4) were analyzed by Dynamic Light Scattering (DLS) in order to determine the micelle sizes and the critical micelle concentrations (cmc's).
De novo phospholipid synthesis: in situ vesicle formation 12.5 µL (10 mM stock solution) of lysolipid (1 or 4) and 15 µL (10 mM stock solution) of thioester 2 were added to 22.5 µL of HEPES buffer (100 mM, pH 7.5) at r.t., and the mixture was briefly agitated. The resulting solution was added to a glass microscope slide and covered with a glass coverslip supported with vacuum grease. The sample was then monitored by phase contrast microscopy in order to analyze the in situ phospholipid (3 or 5) vesicle formation.
HPLC/ELSD/MS Analysis
De novo formation of phospholipid membranes were performed in the appropriate buffer (100 mM HEPES pH 7.5 buffer) as described above. Aliquots of 7.5 µL of sample were taken at various time points, diluted with 92.5 µL of MeOH and analyzed using an Eclipse Plus C8 analytical column (5% Phase A in Phase B, 5. 
Encapsulation Experiments
Encapsulation of HPTS (Standard method). 10 µL of a 10 mM solution of phospholipid (3 or 5) in MeOH:CHCl 3 (1:1) were added to a glass vial, placed under a steady flow of N 2 and dried for 10 min to prepare a lipid film. Then, 100 µL of 0.1 mM HPTS aqueous solution were added to the lipid film and briefly vortexed. The solution was tumbled at r.t. for 30 min. Afterward, the resulting cloudy solution was diluted with an additional 200 µL of H 2 O and transferred to a 100 kDa molecular weight cut-off (MWCO) centrifugal membrane filter and centrifuged for 3 min at 10,000 rcf (Eppendorf 5415C). The solution was similarly washed for additional 5 times to remove any nonencapsulated dye. Then, 5 µL of the vesicle solution were placed on a clean glass slide, secured by a greased cover slip and imaged on a spinning disc confocal microscope (488 nm laser) to observe encapsulation of HPTS.
In situ encapsulation of EGFP. 25.0 µL (10 mM stock solution) of lysolipid (1 or 4) and 30 µL (10 mM stock solution) of thioester 2 were added to 45.0 µL of HEPES buffer (100 mM, pH 7.5). Then, 2.0 µL of 220 µM solution of EGFP were added and the solution was kept at r.t. for 24 h. The resulting solution was diluted with an additional 200 µL of 45 mM HEPES buffer pH 7.5, transferred to a 100 kDa MWCO centrifugal membrane filter and centrifuged for 3 min at 10,000 rcf (Eppendorf 5415C). The solution was similarly washed for additional 4 times to remove any non-encapsulated EGFP. Afterward, 5 µL of the vesicle solution were placed on a clean glass slide, secured by a greased cover slip and imaged on a spinning disc confocal microscope (488 nm laser) to observe encapsulation of EGFP in the in situ formed vesicles. 
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Figure S2
Dynamic Light Scattering corresponding to 100 µM aqueous solution of lysolipid 1 (A), thioester 2 (B) and lysolipid 4 (C). All the precursors show critical micelle concentrations (cmc's) below 10 µM. 3 Micelle sizes were approximately 8.9 nm for both lysolipids and 3.8 nm for the thioester.
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Figure S3
Fluorescence microscopy image of the membrane-containing vesicles formed by spontaneous assembly directed by HL-based synthesis of phospholipid 5. Membranes were stained using 1 µm Texas Red ® DHPE dye solution. Scale bar denotes 10 µm.
